Barinthus Biotherapeutics plc (BRNS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Barinthus Biotherapeutics plc (BRNS) trades at $0.58 with AI Score 37/100 (Weak). Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel T cell immunotherapeutics. Market cap: 24M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Barinthus Biotherapeutics plc (BRNS) Healthcare & Pipeline Overview
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, pioneers T cell immunotherapeutics targeting chronic infectious diseases, autoimmunity, and cancer. Its diverse pipeline, including VTP-300 for HBV and VTP-200 for HPV, positions it within the competitive biotechnology sector, focusing on innovative immune-guided therapies.
Investment Thesis
Barinthus Biotherapeutics presents a high-risk, high-reward investment opportunity centered on its innovative T cell immunotherapeutic pipeline. The company's lead candidate, VTP-300, targeting chronic HBV infection, represents a significant potential value driver. Successful clinical trials and eventual regulatory approval could lead to substantial revenue streams. The company's diverse pipeline, including candidates for HPV, celiac disease, and prostate cancer, provides multiple avenues for growth. However, the company's negative P/E ratio of -0.38 reflects its current lack of profitability and reliance on future clinical and commercial success. Investors should carefully consider the inherent risks associated with clinical-stage biopharmaceutical companies, including clinical trial failures, regulatory hurdles, and competition from established players.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.03 billion reflects the company's early stage and potential for growth.
- Negative P/E ratio of -0.38 indicates the company is not currently profitable, typical for clinical-stage biopharmaceutical firms.
- Beta of -0.62 suggests the stock is less volatile than the overall market.
- Focus on T cell immunotherapeutics positions the company in a high-growth area of biotechnology.
- Pipeline includes multiple product candidates targeting significant unmet medical needs.
Competitors & Peers
Strengths
- Novel T cell immunotherapeutic platforms.
- Diverse pipeline targeting multiple diseases.
- Experienced management team.
- Strong intellectual property portfolio.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on future clinical trial success.
- Limited financial resources.
- Negative P/E ratio.
Catalysts
- Upcoming: Clinical trial results for VTP-300 in chronic HBV infection.
- Upcoming: Clinical trial data release for VTP-200 in persistent high-risk HPV.
- Upcoming: Initiation of clinical trials for VTP-1000 in celiac disease.
- Ongoing: Continued development and advancement of the SNAP-TI and SNAP-CI platforms.
- Ongoing: Potential partnerships or collaborations with larger pharmaceutical companies.
Risks
- Potential: Clinical trial failures for product candidates.
- Potential: Regulatory delays or rejection of marketing applications.
- Ongoing: Competition from established players in the biotechnology industry.
- Ongoing: Dependence on securing additional funding to support research and development.
- Potential: Intellectual property challenges or patent expirations.
Growth Opportunities
- Expansion of VTP-300 for HBV: VTP-300, aimed at a functional cure for chronic HBV infection, represents a significant growth opportunity. The global market for HBV therapeutics is substantial, with an estimated market size of billions of dollars. Successful clinical trials and regulatory approval could lead to significant revenue generation for Barinthus Biotherapeutics. The timeline for potential commercialization depends on clinical trial outcomes, with potential launch in the coming years.
- Advancement of VTP-200 for HPV: VTP-200, a non-surgical product candidate for persistent high-risk HPV, offers another growth avenue. The market for HPV treatments is driven by the prevalence of HPV-related diseases, including cervical cancer. Positive clinical data and subsequent regulatory approval could establish VTP-200 as a valuable treatment option. Clinical trials are ongoing, with potential for market entry within the next few years.
- Development of VTP-1000 for Celiac Disease: VTP-1000, utilizing the SNAP-TI platform for celiac disease, addresses a significant unmet need in autoimmune disorders. The market for celiac disease treatments is growing, driven by increased diagnosis rates and awareness. Successful development and commercialization of VTP-1000 could provide a competitive advantage. Clinical development is underway, with potential for future expansion.
- Progress of VTP-850 for Prostate Cancer: VTP-850, a second-generation immunotherapeutic for recurrent prostate cancer, targets a major area of oncology. The prostate cancer therapeutics market is substantial, with continuous demand for novel treatments. Positive clinical results and regulatory approval could position VTP-850 as a valuable asset. Clinical trials are in progress, with potential for future market entry.
- Exploitation of SNAP-CI Platform for HPV-Related Cancers: VTP-1100, a preclinical cancer candidate utilizing the SNAP-CI platform for HPV-related cancers, represents a longer-term growth opportunity. The market for HPV-related cancer therapies is driven by the prevalence of these cancers and the need for more effective treatments. Successful preclinical development and subsequent clinical trials could lead to a valuable addition to the company's pipeline. Preclinical studies are ongoing.
Opportunities
- Partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Advancement of pipeline candidates through clinical trials.
- Potential for breakthrough therapies in areas of unmet need.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established players.
- Patent challenges.
Competitive Advantages
- Proprietary T cell immunotherapeutic platforms (SNAP-TI and SNAP-CI).
- Pipeline of product candidates targeting significant unmet medical needs.
- Expertise in developing immunotherapies for chronic infectious diseases, autoimmunity, and cancer.
- Intellectual property protection for its product candidates and platforms.
About BRNS
Founded in 2016 and headquartered in Harwell, United Kingdom, Barinthus Biotherapeutics plc, formerly known as Vaccitech plc until November 2023, is a clinical-stage biopharmaceutical company dedicated to developing novel T cell immunotherapeutics. These therapies are designed to guide the immune system in overcoming chronic infectious diseases, autoimmunity, and cancer. The company's pipeline includes several product candidates across a range of therapeutic areas. VTP-300 is an immunotherapeutic candidate aimed at becoming a component of a functional cure for chronic HBV infection. VTP-200 is a non-surgical product candidate targeting persistent high-risk human papillomavirus (HPV). VTP-1000 is an autoimmune candidate utilizing the SNAP-TI platform to treat patients with celiac disease. VTP-850 is a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Finally, VTP-1100 is a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. Barinthus Biotherapeutics focuses on innovative approaches to harness the power of the immune system to address significant unmet medical needs.
What They Do
- Develop novel T cell immunotherapeutics.
- Target chronic infectious diseases such as HBV.
- Develop treatments for autoimmune diseases like celiac disease.
- Create immunotherapies for cancers, including prostate cancer and HPV-related cancers.
- Utilize proprietary platforms like SNAP-TI and SNAP-CI.
- Advance product candidates through clinical trials.
Business Model
- Focus on research and development of T cell immunotherapeutics.
- Out-licensing or partnering with larger pharmaceutical companies for commercialization.
- Securing funding through venture capital, public offerings, and grants.
- Generating revenue through milestone payments and royalties from partnered products.
Industry Context
Barinthus Biotherapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for immunotherapies is experiencing substantial growth, driven by advancements in understanding the immune system and its role in fighting diseases. Barinthus Biotherapeutics' focus on T cell immunotherapeutics aligns with this trend, positioning it to potentially capitalize on the increasing demand for innovative treatments for chronic infectious diseases, autoimmunity, and cancer. Competitors include companies like ALGS, CVM, INMB, KPTI, and KZR, each pursuing different approaches within the immunotherapy space.
Key Customers
- Patients suffering from chronic HBV infection.
- Individuals with persistent high-risk HPV.
- Patients diagnosed with celiac disease.
- Individuals with recurrent prostate cancer.
- Patients with HPV-related cancers.
Financials
Chart & Info
Barinthus Biotherapeutics plc (BRNS) stock price: $0.58 (+0.03, +5.49%)
Latest News
-
Barinthus Biotherapeutics Q4 EPS $(0.27) Beats $(0.40) Estimate
benzinga · Mar 13, 2026
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · Mar 13, 2026
-
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
Yahoo! Finance: BRNS News · Mar 13, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Mar 10, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRNS.
Price Targets
Wall Street price target analysis for BRNS.
MoonshotScore
What does this score mean?
The MoonshotScore rates BRNS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Barinthus Biotherapeutics Q4 EPS $(0.27) Beats $(0.40) Estimate
12 Health Care Stocks Moving In Friday's Pre-Market Session
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
12 Health Care Stocks Moving In Tuesday's After-Market Session
Leadership: William J. Enright
Chief Executive Officer
William J. Enright serves as the Chief Executive Officer of Barinthus Biotherapeutics plc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and commercialization. He has held leadership positions at various biotechnology companies, contributing to the development and launch of multiple pharmaceutical products. His expertise spans across various therapeutic areas, including infectious diseases, oncology, and autoimmune disorders. He manages 105 employees at Barinthus Biotherapeutics plc.
Track Record: Under William J. Enright's leadership, Barinthus Biotherapeutics plc has focused on advancing its pipeline of T cell immunotherapeutics. Key milestones include the progression of VTP-300 into clinical trials for chronic HBV infection and the continued development of VTP-200 for HPV. The company's strategic shift towards immunotherapies reflects his vision for addressing significant unmet medical needs.
Barinthus Biotherapeutics plc ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. For Barinthus Biotherapeutics plc (BRNS), each ADR represents a specific number of ordinary shares of the company held by a depositary bank. This allows U.S. investors to invest in BRNS without directly dealing with foreign markets.
- Home Market Ticker: London Stock Exchange, United Kingdom
- ADR Level: 2
- ADR Ratio: 1:1
Barinthus Biotherapeutics plc Stock: Key Questions Answered
What does Barinthus Biotherapeutics plc do?
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel T cell immunotherapeutics. These therapies are designed to harness the power of the immune system to treat chronic infectious diseases, autoimmunity, and cancer. The company's pipeline includes product candidates targeting HBV, HPV, celiac disease, and prostate cancer, utilizing proprietary platforms like SNAP-TI and SNAP-CI. Barinthus Biotherapeutics aims to address significant unmet medical needs through innovative immunotherapeutic approaches.
What do analysts say about BRNS stock?
As of 2026-03-15, analyst coverage of Barinthus Biotherapeutics plc (BRNS) is limited, reflecting its clinical-stage status and relatively small market capitalization. Key valuation metrics are influenced by the company's potential future earnings from its pipeline candidates. Growth considerations center on the successful completion of clinical trials and regulatory approvals. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in clinical-stage biopharmaceutical companies. Analyst consensus is Unknown.
What are the main risks for BRNS?
The main risks for Barinthus Biotherapeutics plc include clinical trial failures, regulatory hurdles, and competition from established players in the biotechnology industry. The company's success depends on the positive outcomes of clinical trials for its product candidates, and any setbacks could significantly impact its value. Regulatory delays or rejection of marketing applications could also hinder the company's progress. Additionally, Barinthus Biotherapeutics faces competition from larger pharmaceutical companies with greater resources and established market presence.
What are the key factors to evaluate for BRNS?
Barinthus Biotherapeutics plc (BRNS) currently holds an AI score of 37/100, indicating low score. Key strength: Novel T cell immunotherapeutic platforms.. Primary risk to monitor: Potential: Clinical trial failures for product candidates.. This is not financial advice.
How frequently does BRNS data refresh on this page?
BRNS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BRNS's recent stock price performance?
Recent price movement in Barinthus Biotherapeutics plc (BRNS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel T cell immunotherapeutic platforms.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BRNS overvalued or undervalued right now?
Determining whether Barinthus Biotherapeutics plc (BRNS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BRNS?
Before investing in Barinthus Biotherapeutics plc (BRNS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and thorough research.